线粒体功能障碍、α-突触核蛋白与帕金森病

doi:10.3969/j.issn.1006-7795.2015.06.006

首都医科大学学报 ›› 2015, Vol. 36 ›› Issue (6): 861-864.doi: 10.3969/j.issn.1006-7795.2015.06.006

• 神经系统疾病的基础研究 • 上一篇下一篇

线粒体功能障碍、α-突触核蛋白与帕金森病

张如意, 张丽, 李林

首都医科大学宣武医院药物研究室北京市老年病医疗研究中心北京市神经药物工程技术研究中心, 北京 100053

收稿日期:2015-10-10 出版日期:2015-12-21 发布日期:2015-12-18
通讯作者: 李林 E-mail:linlixw@126.com
基金资助:
国家自然科学基金项目(81341087,81273498),首都卫生发展科研专项(2011-1001-04)。

Mitochondrial dysfunction, α-synuclein and Parkinson's disease

Zhang Ruyi, Zhang Li, Li Lin

Department of Pharmacology, Xuanwu Hospital, Capital Medical University, Beijing Geriatric Medical Research Center, Beijing Engineering Research Center for Nerve System Drugs, Beijing 100053, China

Received:2015-10-10 Online:2015-12-21 Published:2015-12-18
Supported by:
This study was supported by National Natural Science Foundation of China(81341087, 81273498);The Capital Health Research and Development of Special Project(2011-1001-04).

摘要/Abstract

摘要： 帕金森病(Parkinson's disease,PD)是以中脑黑质多巴胺能神经元缺失,黑质残存神经元内出现路易小体为主要病理改变的神经退行性疾病。越来越多的证据显示线粒体复合体Ⅰ功能障碍是散发性PD的核心发病机制,α-突触核蛋白(α-synuclein,α-Syn)异常聚集是PD病理学级联反应的关键事件。近年来,α-Syn与线粒体功能障碍的关系尤其引人注意,但至今对它们在PD中的作用机制并不完全清楚,二者间的相互作用尚不明确。本文综述了α-Syn与线粒体在PD发病中的关键作用以及二者在PD发病中的相互作用。对α-Syn及线粒体在PD发病中发挥作用的机制深入了解将对研发新的PD治疗方法具有重要意义。

关键词: 帕金森病, α-突触核蛋白, 线粒体

Abstract: Parkinson's disease(PD) is a common neurodegenerative disorder. The disease is characterized by the loss of dopamine neurons in the substantia nigra and the presence of intraneuronal Lewy bodies. Many studies suggest that mitochondrial dysfunction is the central pathogenesis of PD. The abnormal aggregation of α-synuclein is the key factor in the cascade of PD pathological events. Recently, the interaction between α-synuclein and mitochondrial dysfunction has attracted much attention, but the exact mechanism underlying PD pathogenesis is still unclear. In this review, we discuss the key roles of mitochondria and α-synuclein in the pathogenesis of PD and the interaction between them. Understanding the functional consequences of α-synuclein's interactions with mitochondria is likely to provide important insights into disease pathophysiology, and may also reveal therapeutic strategies.

Key words: Parkinson's disease, α-Synuclein, mitochondria

中图分类号:

R741

张如意, 张丽, 李林. 线粒体功能障碍、α-突触核蛋白与帕金森病[J]. 首都医科大学学报, 2015, 36(6): 861-864.

Zhang Ruyi, Zhang Li, Li Lin. Mitochondrial dysfunction, α-synuclein and Parkinson's disease[J]. Journal of Capital Medical University, 2015, 36(6): 861-864.

参考文献

[1] Bekris L M, Mata I F, Zabetian C P. The genetics of Parkinson disease[J]. J Geriatr Psychiatry Neurol, 2010,23(4):228-242.
[2] Peng X, Tehranian R, Dietrich P, et al.Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells[J]. J Cell Sci, 2005,118(Pt15):3523-3530.
[3] Zhao D L, Zou L B, Zhou L F, et al. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease[J]. Acta Pharmacol Sin, 2007,28(5):616-626.
[4] Perez R G, Waymire J C, Lin E, et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis[J]. J Neurosci, 2002,22(8):3090-3099.
[5] Koch J C, Bitow F, Haack J, et al. Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons[J]. Cell Death Dis, 2015,6:e1811.
[6] Prots I, Veber V, Brey S, et al. α-Synuclein oligomers impair neuronal microtubule-kinesin interplay[J]. J Biol Chem, 2013,288(30):21742-21754.
[7] Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease[J]. Nat Genet, 2009,41(12):1303-1307.
[8] Lee V M, Trojanowski J Q. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery[J]. Neuron, 2006,52(1):33-38.
[9] Volpicelli-Daley L A, Luk K C, Patel T P, et al. Exogenous α-synuclein fibrils induce Lewy bod pathology leading to synaptic dysfunction and neuron death[J]. Neuron, 2011,72(1):57-71.
[10] Gómez-Santos C, Ferrer I, Reiriz J, et al. MPP+ increases α-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells[J]. Brain Res, 2002,935(1-2):32-39.
[11] Banerjee R, Starkov A A, Beal M F, et al. Mitochondrial dysfunction in the limlight of Parkinson's disease pathogenesis[J]. Biochim Biophys Acta, 2009,1792(7):651-663.
[12] Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology[J]. Cell Tissue Res, 2004,318(1):121-134.
[13] De Vos K J, Grierson A J, Ackerley S, et al. Role of axonal transport in neurodegenerative diseases[J]. Annu Rev Neurosci, 2008,31:151-173.
[14] Roy S. The paradoxical cell biology of α-synuclein[J]. Results Probl Cell Differ, 2009,48:159-172.
[15] Schapira A H. Cooper J M, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease[J]. J Neurochem, 1990,54(3):823-827.
[16] Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance[J]. Ann N Y Acad Sci, 2008,1147:93-104.
[17] Ferrer I. Neuropathology and neurochemistry of non motor symptoms in Parkinson's disease[J]. Parkinsons Dis, 2011:708404.
[18] Zaminelli T, Gradowski R W, Bassani T B, et al. Antidepressant and antioxidative effect of ibuprofen in the rotenone model of Parkinson's disease[J]. Neurotox Res, 2014,26(4):351-362.
[19] Jiang H, Wu Y C, Nakamura M, et al. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H₂O₂- and Sin-1-induced cell death[J]. Neurobiol Aging, 2007,28(11):1709-1717.
[20] Parihar M S, Parihar A, Fujita M, et al. Mitochondrial association of alpha-synuclein causes oxidative stress[J]. Cell Mol Life Sci, 2008,65(7-8):1272-1284.
[21] Wu F, Poon W S, Lu G, et al. α-Synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells[J]. Brain Res, 2009,1292:173-179.
[22] Martin L J, Pan Y, Price A C, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death[J]. J Neurosci, 2006,26(1):41-50.
[23] Betts-Henderson J, Jaros E, Krishnan K J, et al. Alpha-synuclein pathology and Parkinsonism associated with POLG1 mutations and multiple mitochondrial DNA deletions[J]. Neuropathol Appl Neurobiol, 2009,35(1):120-124.
[24] Chinta S J, Mallajosyula J K, Rane A, et al. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo[J]. Neurosci Lett, 2010,486(3):235-239.
[25] Devi L, Raghavendran V, Prabhu B M, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain[J]. J Biol Chem, 2008,283(14):9089-9100.
[26] Nakamura K, Nemani V M, Wallender E K, et al. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria[J]. J Neurosci, 2008,28(47):12305-12317.
[27] Nakamura K, Nemani V M, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein[J]. J Biol Chem, 2011,286(23):20710-20726.
[28] Xie W, Chung K K. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease[J]. J Neurochem, 2012,122(2):404-414.
[29] Dawson T M, Ko H S, Dawson V L. Genetic animal models of Parkinson's disease[J]. Neuron, 2010,66(5):646-661.
[30] Zhang N Y, Tang Z, Liu C W. alpha-Synuclein protofibrils inhibit 26S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis[J]. J Biol Chem, 2008,283(29):20288-20298.

线粒体功能障碍、α-突触核蛋白与帕金森病

Mitochondrial dysfunction, α-synuclein and Parkinson's disease

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王梦迪, 郭弋凡, 庞彦余, 刘羽飞, 赵文景. 保肾通络方含药血清调节线粒体自噬对高糖诱导下足细胞氧化损伤的影响[J]. 首都医科大学学报, 2022, 43(5): 687-693.
[2]	何颖, 冯传良, 刘进营, 郑慧敏, 江圣杰. 三维微环境手性特征调控间充质干细胞线粒体功能[J]. 首都医科大学学报, 2022, 43(3): 440-445.
[3]	粟文婷, 於佳楠, 贾军, 王晓民. 电针对帕金森病模型小鼠纹状体背侧的c-Fos表达的选择性调节[J]. 首都医科大学学报, 2021, 42(6): 986-992.
[4]	高歌, 查旭, 刘伟进, 杨慧. 129位丝氨酸磷酸化α-突触核蛋白DELFIA检测方法的建立及初步应用[J]. 首都医科大学学报, 2021, 42(5): 776-782.
[5]	王梦月, 赵鑫, 曹枭, 王可, 贾军. 帕金森病小鼠模型自主活动状态下的运动启动分析[J]. 首都医科大学学报, 2021, 42(4): 553-558.
[6]	丁锚, 杨楠, 黄语悠, 师文娟, 闫峰, 赵咏梅, 刘克建. 线粒体活性氧自由基抑制剂R(+)-普拉克索对脑缺血再灌注损伤大鼠JAK2-STAT3通路及炎性因子TNF-α的影响[J]. 首都医科大学学报, 2021, 42(2): 232-238.
[7]	崔兴, 钟萍. 我的梦想是做“百年老店”——记首都医科大学三博脑科医院神经外科于春江教授[J]. 首都医科大学学报, 2021, 42(1): 167-169.
[8]	袁惠莉, 宫晓丽, 范征, 梁志刚, 王晓民. 远志皂苷对脂多糖诱导的帕金森病模型大鼠的作用及机制研究[J]. 首都医科大学学报, 2020, 41(6): 914-922.
[9]	王明洋, 孙争宇, 张丽, 李雅莉, 李林, 张兰. 山茱萸环烯醚萜苷对脑缺血再灌注大鼠线粒体损伤的影响[J]. 首都医科大学学报, 2020, 41(3): 385-390.
[10]	宋启晗, 李旭冉, 李昕, 杨巍巍, 李伟, 于顺. 不同亚型的帕金森病及多系统萎缩患者血浆α-突触核蛋白寡聚体浓度分析[J]. 首都医科大学学报, 2020, 41(2): 212-216.
[11]	丁晖, 蔡彦宁, 陈彪. 灵芝提取物对MPP⁺诱导的Neuro-2a细胞自噬的影响[J]. 首都医科大学学报, 2019, 40(4): 596-601.
[12]	王兆佳, 武烨, 刘丹, 王美丽, 隗歆, 刘慧荣. 不同浓度β₁-肾上腺素受体自身抗体对心肌细胞存活影响的差异性[J]. 首都医科大学学报, 2019, 40(3): 402-408.
[13]	张辉, 马惠清, 王森茂, 王晓娟. 银杏叶提取物对帕金森病模型大鼠脑内神经炎性反应的影响[J]. 首都医科大学学报, 2019, 40(3): 439-442.
[14]	李杰, 谢秀娟, 宋炜, 潘维花, 杨巍巍, 于顺. 帕金森病患者血浆增强α-突触核蛋白细胞毒性及其机制研究[J]. 首都医科大学学报, 2019, 40(2): 244-250.
[15]	辛明蔚, 何军琴, 贾朝霞, 武颖, 张莹, 杨维, 尹晓丹. 温肾养血方提高高龄雌鼠卵母细胞质量和胚胎发育潜能的研究[J]. 首都医科大学学报, 2018, 39(6): 815-820.